Marksans Pharma Limited has informed the Exchange regarding a press release dated May 26, 2026, titled "Marksans Pharma Marksans Pharma Hits Historic Triple: Highest Revenue, EBITDA & PAT ₹3,000 Cr Net Income Guidance Delivered".
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Marksans Pharma reported record FY26 performance with total income of Rs 3,033 crore (up 12.8% YoY), EBITDA of Rs 601 crore (margin 20.4%), and PAT of Rs 420 crore (up 9.8%). Q4FY26 was particularly strong with revenue of Rs 891 crore (up 23.1% YoY) and PAT of Rs 149 crore (up 64.3% YoY). The US market remains the largest contributor at Rs 1,533 crore (24% growth), while UK showed recovery in Q4. Australia & NZ delivered highest-ever quarterly performance. The company launched 112 new SKUs in the US, entered new markets (Germany, Canada, Ireland), and maintained a strong cash position of Rs 990 crore with net cash positive status.
The company delivered on its guidance with all-time high financials across revenue, EBITDA and PAT, indicating strong execution. The robust cash balance and improving margins position the stock positively for shareholders, though rising input costs warrant monitoring.